AstraZeneca Completes Divestment of Nexium & Vimovo to Grunenthal
Resilinc-blog

According to ADNKronos, Grunenthal has announced the successful completion of its acquisition of European rights to Nexium and Vimovo from AstraZeneca on Monday, December 3. The total consideration for this deal is $922 million.

Read All Global Disruptions

Recent Global Disruptions